
    
      In this study patients will be enrolled and followed for 24 weeks (natural history phase) at
      which point they will be randomized to 1 of 4 doses of ONL1204 Ophthalmic Solution or sham.
      Weeks 24 to 48 make up the Treatment Phase. Patients will be on study for a total of 48 weeks
      followed by a follow-up period of 24 weeks.
    
  